Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label Phase 1 Study to Evaluate the Safety of PF-08046045/SGN-35T in Adults With Advanced Malignancies

NCT06120504 is registered in ClinicalTrials.gov with Seagen, a wholly owned subsidiary of Pfizer as lead sponsor.

NCT NCT06120504
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06120504 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label Phase 1 Study to Evaluate the Safety of PF-08046045/SGN-35T in Adults With Advanced Malignancies
Lead sponsor
Seagen, a wholly owned subsidiary of Pfizer
Phase
Phase 1
Overall status
Terminated
Start date
February 29, 2024
Completion date
December 10, 2025
Enrollment
22 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

hodgkin disease, lymphoma, large b-cell, diffuse, lymphoma, large-cell, anaplastic, lymphoma, non-hodgkin, lymphoma, t-cell, cutaneous, lymphoma, t-cell, peripheral